CorMedix

Historical price data

CorMedix is a clinical-stage biotech with a mission to address critical unmet needs in hospital-acquired infections, specifically targeting the prevention of catheter-related bloodstream infections in hemodialysis patients. Its primary achievement is the development of DefenCath®, a taurolidine-based lock solution that has received FDA Fast Track and QIDP designations and is under regulatory review. The company's strategy is to successfully navigate the approval and commercialization of DefenCath, which could establish a new standard of care, while leveraging its taurolidine platform for future anti-infective and anti-inflammatory applications.

Centered on taurolidine, a synthetic broad-spectrum antimicrobial and anti-inflammatory agent with a unique, non-antibiotic mechanism of action that cross-links microbial cell walls, leading to cell death without inducing resistance.

DefenCath's primary competition is the current standard of care (heparin lock) and off-label antibiotic locks. Its key advantages are a non-antibiotic mechanism preventing resistance, proven Phase 3 efficacy, and regulatory incentives (QIDP) for exclusivity.